Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 16,071.7	$ 8,497.1	$ 6,557.6
Roche Collaboration Agreement | Casirivimab and imdevimab | Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues	361.8	0.0
Roche Collaboration Agreement | Casirivimab and imdevimab | Research and development expense
Disaggregation of Revenue [Line Items]
Revenues	128.1	78.5
Roche Collaboration Agreement | Casirivimab and imdevimab | Cost of goods sold
Disaggregation of Revenue [Line Items]
Revenues	$ 259.6	$ 0.0